期刊文献+

Tau蛋白表达与复发转移性乳腺癌紫杉醇化疗敏感性关系

The relationship of Tau protein expression with the sensitivity in taxane chemotherapy of recurrent and metastatic breast cancer
下载PDF
导出
摘要 目的探讨复发转移性乳腺癌组织中Tau蛋白的表达情况及其与紫杉醇药物姑息性化疗敏感性的相关性。方法采用免疫组化Envision二步法检测136例复发转移性乳腺癌患者转移病灶的组织样本中Tau蛋白的表达水平,χ2检验或Fisher精确概率法分析其与复发转移性乳腺癌临床病理特征及与紫杉醇类药物姑息性化疗敏感性的关系。结果复发转移性乳腺癌患者Tau蛋白的阳性表达率为28.68%(39/136),Tau蛋白的阳性表达与患者的年龄、身体密度、ECOG分值、病理分型、组织学分级、孕激素受体、表皮生长因子受体-2、增殖指数Ki-67及P53阳性表达均无相关性,但与乳腺癌组织的雌激素受体表达相关(P<0.05)。而且,Tau蛋白的表达与紫杉醇药物性化疗疗效相关(P<0.01)。结论 Tau蛋白表达水平与复发转移性乳腺癌紫杉醇类药物姑息性化疗敏感性呈负相关,临床检测Tau蛋白表达可能可作为复发转移性乳腺癌行紫杉醇类药物性姑息性化疗方案的选择依据。 ObjectiveTo investigate the expression of Tau protein in recurrent and metastatic breast cancer and the correlation between Tau protein and the effect of taxane-containing palliative chemotherapy. MethodsThe expression of Tao protein in the metastatic breast tumor tissue of 136 patients with recurrent and metastatic breast cancer was detected by immunohistochemistry.The correlation between the expression of Tao protein and clinical variables, such as taxane sensitivity and the associations between Tau expression and the efficiency of taxane-containing palliative chemotherapy was used by χ2 test or Fisher exact probability test. ResultsThe expression of Tau protein in thirty-nine (28.68%, 39/136) patients was positive. The expression of Tau protein was positively related to ER (P〈0.05) and negatively related with the effect of taxanes-containing palliative chemotherapy (P〈0.01). ConclusionThe expression of Tau protein was negatively related with the effect of taxane-containing palliative chemotherapy. The detection of the expression of Tau protein in recurrent and metastatic breast cancer may be a clinical basis to choose taxane-containing palliative chemotherapy.
出处 《岭南现代临床外科》 2014年第2期153-156,共4页 Lingnan Modern Clinics in Surgery
基金 广州市医药卫生科技项目(编号:20121A011166)
关键词 TAU蛋白 复发转移 乳腺癌 紫杉醇 Tau protein Recurrent and metastatic Breast cancer Taxane
  • 相关文献

参考文献11

  • 1Rouzier R, Rajan R, Wagner P, et al. Microtubule associated protein tau: a marker of paclitaxel sensitivity in breast cancer [J]. Proc Natl Acad Sci U S A, 2005, 102 (23) : 8315-8320.
  • 2Wagner P, Wang B, Clark E, et al. Microtubule associated protein (MAP)-Tau: a novel mediator of paclitaxel sensitivity in vitro and in vivo[J]. Cell Cycle, 2005,4(9):1149-1152.
  • 3王坤,邓权通,廖宁,祖健,张国淳,李学瑞,姚濛,郑登云.蛋白tau表达与乳腺癌紫杉类新辅助化疗敏感性的关系[J].中华肿瘤防治杂志,2011,18(3):187-190. 被引量:6
  • 4Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) [J]. Eur J Cancer, 2009, 45(2): 228-247.
  • 5Gines J, Sabater E, Martorell C, et al. Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta- analysis of randomised clinical trials [J]. Clin Transl Oncol, 2011, 13(7): 485-498.
  • 6Tommasi S, Mangia A, Lacalamita R, etal. Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta- tubulins [Jl. Int J Cancer, 2007, 120(10): 2078-2085.
  • 7Basu A, DuBois G, Haldar S. Posttranslational modifications of Bel2 family members-a potential therapeutic target for human malignancy [J]. Front Biosci, 2006, 11: 1508-1521.
  • 8Chen X, Wu J, Lu H, et al. Measuring β-tubulin Ⅲ, Bcl- 2, and ERCC1 improves pathological complete remission predictive accuracy inbreast cancer [J]. Cancer Sci, 2012,103(2): 262-268.
  • 9Robert M, Mathuranath PS. Tau and taupathies [J]. Neurol India, 2007, 55(1): 11-16.
  • 10Andre F, Hatzis C, Anderson K, et al. Microtubule associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptorp- ositive breast cancer [J]. Clin Cancer Res, 2007, 13 (7): 2061-2067.

二级参考文献10

  • 1王丕琳,李玉文,尹子毅,张铁,朱强,智迎辉.表柔比星联合紫杉醇对浸润性乳腺癌新辅助化疗临床研究[J].中华肿瘤防治杂志,2007,14(9):698-700. 被引量:5
  • 2Priya R, Stewart J A,Harry D B,et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel pro- ject protocols 13-18 and B-27[J]. J Clin Oncol, 2008, 26(5): 778-785.
  • 3Mamounas E P, Bryant J, Lembersky B C, et al. Paclitaxel af ter doxorubiein plus cyclophosphamide as adjuvant chemotherapy for node positive breast cancer: Results from NSABP-B 28[J]. J Clin Oncol, 2005, 23(16) :3686-3696.
  • 4Rouzier R, Rajan R, Wagner P, et al. Microtubule-associated protein tau: a marker of paclitaxeI sensitivity in breast cancer [J]. ProcNatlAcadSciUSA, 2005, 102(23) :8315-8320.
  • 5Mazouni C, Peintinger F, Wan-Kau S, et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not ad versely affect patient outeome[J]. J Clin Oncol, 2007,25 (19) : 2650-2655.
  • 6Ikeda H, Taira N, Hara F, et al. The estrogen receptor influ ences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant down regulates MAPT and increases the sensitivity to taxane in breast cancer cells[J]. Breast Cancer Res, 2010,12(3) :R43.
  • 7Andre F, Hatzis C, Anderson K, et al. Mierotubule associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor positive breast cancer[J]. Clin Cancer Res, 2007, 13(7):2061-2067.
  • 8Pusztai L, Jeong J H, Gong Y, et al. Evaluation of microtubule-associated protein-tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial[J]. J Clin Oncol, 2009, 27(26): 4287-4292.
  • 9Andre F, Mazouni C, Liedtke C, et al. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer[J]. Breast Cancer Res Treat, 2008, 108(2):183-190.
  • 10Hess K R, Anderson K, Symmans W F, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paelitaxel and fluorouracil, doxorubiein, and cyclophosphamide in breast cancer [J]. J Clin Oncol, 2006, 24(26):4236-4244.

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部